Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models

29 Sept 2021

Abstract excerpt

Interactions between WD40 repeat domain protein 5 (WDR5) and its various partners such as mixed lineage leukemia (MLL) and c-MYC are essential for sustaining oncogenesis in human cancers. However, inhibitors that block protein-protein interactions (PPIs) between WDR5 and its binding partners exhibit modest cancer cell killing effects and lack in vivo efficacy. Here, we present pharmacological degradation of WDR5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34586829
DOI: 10.1126/scitranslmed.abj1578

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse modelsPMID 34586829Read ↗

Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.Semantic proximity Read ↗

Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC InteractionSemantic proximity Read ↗

Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5–Mixed Lineage Leukemia 1 Protein–Protein Interaction for the Treatment of MLL Fusion LeukemiaSemantic proximity Read ↗

Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibitionSemantic proximity Read ↗

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in NeuroblastomaSemantic proximity Read ↗

Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcomaSemantic proximity Read ↗

Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.Semantic proximity Read ↗

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic CancerSemantic proximity Read ↗

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of GlioblastomaSemantic proximity Read ↗

Probing the Cancer Mutational Landscape of KMT2 Regulatory Subunits.Semantic proximity Read ↗

HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 ProteinSemantic proximity Read ↗

Targeting human SET1/MLL family of proteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.